文献速递妇科

复发性或持续性妇科恶性肿瘤盆腔廓清术后的预后因素分析

Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort.
PubMed 文献 · Gynecol Oncol · 2021-09-10

该回顾性队列纳入2010至2018年因复发性或进展性子宫、宫颈、阴道或外阴癌行盆腔廓清术且获完全切除的71例患者。中位总生存55.1个月,中位随访40.8个月。单因素分析显示年龄>62岁、ASA 3-4级及外阴癌与更差总生存相关,多因素分析无显著因素。

要点

  • 盆腔廓清术可用于经严格筛选的复发性妇科恶性肿瘤患者,以治愈为目的。
  • 年龄>62岁、ASA 3-4级及外阴癌在单因素分析中与更差总生存相关。
  • 肿瘤大小及既往无进展间期在总生存分析中未达统计学显著性。

核心结论

  • 以治愈为目的的盆腔廓清术可考虑用于经过充分咨询和严格筛选的患者,与肿瘤大小及术前无进展间期无关。

研究设计与样本

  • 单中心回顾性队列研究,纳入2010年1月1日至2018年12月31日因复发性或进展性子宫、宫颈、阴道或外阴癌行盆腔廓清术且组织学证实完全切除的71例患者。

主要发现

  • 中位总生存期为55.1个月(95%CI:36-不可估计),中位随访时间为40.8个月(95%CI:1-116.1)。
  • 原发诊断以外阴癌最常见(32%),其次为宫颈癌(30%)、子宫癌(23%)和阴道癌(15%)。
  • 单因素分析中,年龄>62岁(HR 2.71,95%CI 1.27-5.79)、ASA 3-4级(HR 3.41,95%CI 1.03-11.29)及外阴癌(HR 4.19,95%CI 1.17-14.96)预测更差总生存。
  • 多因素分析中无因素与更差总生存显著相关。

临床怎么用

  • 对复发性或持续性妇科恶性肿瘤患者,在充分咨询和严格筛选后,可考虑以治愈为目的的盆腔廓清术。

局限性

  • 回顾性单中心设计,样本量有限(71例),多因素分析未发现显著预后因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore pre-operative factors and their impact on overall survival (OS) in a modern cohort of patients who underwent pelvic exenteration (PE) for gynecologic malignancies. METHODS: A retrospective review was performed for all patients who underwent a PE from 1/1/2010 through 12/31/2018 at our institution. Inclusion criteria were exenteration due to recurrent or progressive carcinoma of the uterus, cervix, vagina or vulva, with histologically confirmed complete surgical resection of the malignancy. Exclusion criteria included PE for palliation of symptoms without recurrence, and for ovarian or rare histologic malignancies. Univariable and multivariable analysis were performed to identify factors predicting prolonged survival. RESULTS: Overall, 71 patients met the inclusion criteria. Median age at time of exenteration was 62 years (range, 28-86 years). Vulvar cancer was the most common primary diagnosis (32%); 30% had cervical cancer; 23%, uterine cancer; 15%, vaginal cancer. Median OS was 55.1 months (95% confidence interval (CI): 36-not estimable) with a median follow-up time of 40.8 months (95% CI: 1-116.1). On univariable analysis, age > 62 years (hazard ratio (HR) 2.71, 95% CI 1.27-5.79), American Society of Anesthesia (ASA) 3-4 (HR: 3.41 (95% CI 1.03-11.29), and vulvar cancer (HR 4.19 (95% CI 1.17-14.96) predicted worse OS. Tumor size and prior progression-free interval (PFI) did not meet statistical significance in OS analyses. On multivariable analysis, there were no significant factors associated with worse OS. CONCLUSIONS: PE performed with curative intent may be considered a treatment option in well-counseled, carefully selected patients, irrespective of tumor size and PFI before exenteration.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Straubhar AM, Chi AJ, Zhou QC, et al. Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort. Gynecol Oncol. 2021. PMID: 34518053. doi:10.1016/j.ygyno.2021.08.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。